Correlation between new sarcopenia index and bone mineral density in postmenopausal patients with type 2 diabetes mellitus

doi:10.12307/2023.526

Abstract

Abstract: BACKGROUND: The prevalence of type 2 diabetes mellitus complicated with osteoporosis is increasing yearly. Early prevention, detection, and treatment of osteoporosis are considered essential in postmenopausal patients with type 2 diabetes mellitus.
OBJECTIVE: To investigate the correlation of new sarcopenia index (SI) with bone mineral density and osteoporosis in patients with type 2 diabetes mellitus complicated with osteoporosis.
METHODS: Postmenopausal patients with type 2 diabetes mellitus hospitalized in the First Affiliated Hospital, Guangzhou University of Chinese Medicine from January 2021 to March 2022 were selected and divided into osteoporosis group (n=93) and non-osteoporosis group (n=121) according to whether type 2 diabetes mellitus is combined with osteoporosis. The demographic data, bone mineral density, blood routine, glucose metabolism, lipid metabolism, and renal function indexes were collected and the SI was calculated. The correlation between clinical indexes and bone mineral density of the lumbar spine, left femoral neck and left hip was analyzed by multivariate linear regression, and the risk factors of osteoporosis in postmenopausal patients with type 2 diabetes mellitus were analyzed by multivariate logistic regression. The predictive values of new SI, serum cystatin C level, and creatinine/serum cystatin C ratio (CCR) in predicting osteoporosis in postmenopausal patients with type 2 diabetes mellitus were analyzed by the receiver operating characteristic curve.
RESULTS AND CONCLUSION: (1) The new SI, serum cystatin C level, and CCR value in the osteoporosis group were lower than those in the non-osteoporosis group (P < 0.05). (2) Multivariate linear regression analysis with adjusted covariates showed that the new SI and CCR were significantly positively correlated with bone mineral density of the lumbar spine, left femoral neck and left hip (βCCR=0.003, 0.001, 0.002, P < 0.05; βSI=0.002, 0.001, 0.002, P < 0.05). The cystatin C level was significantly correlated with bone mineral density of the lumbar spine (βcystatin C=0.09, P < 0.05). (3) Multivariate Logistic regression analysis with adjusted covariates showed that serum cystatin C level, CCR, and new SI were protective factors for osteoporosis in postmenopausal patients with type 2 diabetes mellitus (odds ratio=0.149, 0.957, 0.941; P < 0.05). (4) The area under the receiver operating characteristic curve of the new SI for predicting osteoporosis in such patients was the largest (the area under the curve=0.756), with a sensitivity of 67.8% and a specificity of 72.0%. (5) To conclude, renal function is intrinsically related to bone health. An increased new SI is related to the increase of bone mineral density in postmenopausal patients with type 2 diabetes mellitus, and the risk of osteoporosis can be predicted by the new SI in such patients.

Key words: type 2 diabetes mellitus, osteoporosis, bone mineral density, new sarcopenia index, postmenopausal woman

CLC Number:

Gu Peng, Pu Bin, Chen Junbang, Yue Dan, Xin Qiao, Zeng Zhanpeng, Zheng Xiaohui. Correlation between new sarcopenia index and bone mineral density in postmenopausal patients with type 2 diabetes mellitus[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(31): 5009-5014.

Figures/Tables 8

References

[1] UKON Y, MAKINO T, KODAMA J, et al. Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review. Int J Mol Sci. 2019; 20(10):2557.
[2] RACHNER TD, KHOSLA S, HOFBAUER LC. Osteoporosis: now and the future. New Horizons. 2011;1276(377):87.
[3] OEI L, RIVADENEIRA F, ZILLIKENS MC, et al. Diabetes, Diabetic Complications, and Fracture Risk. Curr Osteoporos Rep. 2015;13(2): 106-115.
[4] SHANBHOGUE VV, MITCHELL DM, ROSEN CJ, et al. Type 2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol. 2016;4(2):159-173.
[5] KASHANI KB, FRAZEE EN, KUKRÁLOVÁ L, et al. Evaluating Muscle Mass by Using Markers of Kidney Function. Crit Care Med. 2017;45(1): e23-e29.
[6] OSAKA T, HAMAGUCHI M, HASHIMOTO Y, et al. decreased the creatinine to cystatin c ratio is a surrogate marker of sarcopenia in patients with type 2. Diabetes Res Clin Pract. 2018;139:52-58.
[7] LIEN YH. Looking for Sarcopenia Biomarkers. Am J Med. 2017;130(5): 502-503.
[8] FU X, TIAN Z, WEN S, et al. A new index based on serum creatinine and cystatin C is useful for assessing sarcopenia in patients with advanced cancer. Nutrition. 2021;82:111032.
[9] REISS J, IGLSEDER B, ALZNER R, et al. Sarcopenia and osteoporosis are interrelated in geriatric inpatients. Z Gerontol Geriatr. 2019;52(7): 688-693.
[10] EDWARDS MH, DENNISON EM, AIHIE SAYER A, et al. Osteoporosis and sarcopenia in older age. Bone. 2015;80:126-130.
[11] SUI SX, WILLIAMS LJ, HOLLOWAY-KEW KL, et al. Skeletal Muscle Health and Cognitive Function: A Narrative Review. Int J Mol Sci. 2021;22(1): 255.
[12] IKEDA K, HORIE-INOUE K, INOUE S. Functions of estrogen and estrogen receptor signaling on skeletal muscle. J Steroid Biochem Mol Biol. 2019;191:105375.
[13] 董旋, 高飞. 2型糖尿病病人血清Cys-C水平与骨质疏松症的相关性分析[J]. 中西医结合心脑血管病杂志,2019,17(16):2521-2524.
[14] 晏丕军, 欧阳芳, 马红艳,等. 2型糖尿病患者血清胱抑素C与骨质疏松的相关性[J]. 山西医科大学学报,2016,47(1):59-63.
[15] 董晓芬, 李香波, 吴震宇,等. 绝经后2型糖尿病合并骨质疏松症患者外周血NLR、PLR、Cys-C水平与骨密度的相关性分析[J]. 临床和实验医学杂志,2022,21(2):174-177.
[16] YOSHII I, CHIJIWA T, SAWADA N. Screening osteoporotic femoral neck without measuring bone mineral density with the use of tartrate resistant acid phosphatase-5b and serum-creatinine-to-cystatin C ratio in Japanese postmenopausal women. J Orthop Sci. 2020;25(4):671-676.
[17] TABARA Y, KOHARA K, OKADA Y, et al. Creatinine to Cystatin C Ratio as a Marker of Bone Property in Older Adults: The J-Shipp Study. J Nutr Health Aging. 2020;24(3):277-281.
[18] 熊丹, 刘丽君, 贺佩祥,等. 2型糖尿病患者内脏脂肪与骨密度及骨折风险的相关性研究[J]. 中国全科医学,2022,25(6):682-688.
[19] GENG Q, GAO H, YANG R, et al. Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence. Int J Biol Sci. 2019;15(1):58-68.
[20] ICONARU L, MOREAU M, KINNARD V, et al. Does the Prediction Accuracy of Osteoporotic Fractures by BMD and Clinical Risk Factors Vary With Fracture Site? JBMR Plus. 2019;3(12):e10238.
[21] 遇呈祥, 陈亮, 邓忠良. 骨密度对骨质疏松性骨折的判断价值[J]. 中国骨质疏松杂志,2012,18(2):127-129.
[22] 戴小宇, 黄智慧, 王珂杰, 等. 血清钙磷乘积预测老年椎体压缩性骨折风险的意义[J]. 中国骨质疏松杂志,2022,28(4):505-508.
[23] 朱秀洁, 王禹, 于同, 等. 血尿酸与骨密度相关性的研究进展[J]. 中国骨质疏松杂志,2017,23(12):1664-1667.
[24] 王玲, 袁伟杰, 谷立杰, 等. 慢性肾脏病患者骨代谢与尿蛋白量的关系[J]. 中华肾脏病杂志,2010,26(9):667-670.
[25] KAJI H, YAMAUCHI M, YAMAGUCHI T, et al. Mild Renal Dysfunction Is a Risk Factor for a Decrease in Bone Mineral Density and Vertebral Fractures in Japanese Postmenopausal Women. J Clin Endocrinol Metab. 2010;95(10):4635-4642.
[26] KIM H, PARK IY, CHOI JM, et al. A Decline in Renal Function is Associated With Loss of Bone Mass in Korean Postmenopausal Women With Mild Renal Dysfunction. J Korean Med Sci. 2011;26(3):392.
[27] HSU C, CHEN L, CHEN K. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review. Int J Mol Sci. 2020;21(18):6846.
[28] CANNATA-ANDÍA JB, MARTÍN-CARRO B, MARTÍN-VÍRGALA J, et al. Chronic Kidney Disease—Mineral and Bone Disorders: Pathogenesis and Management. Calcif Tissue Int. 2021;108(4):410-422.
[29] SHIMADA T, HASEGAWA H, YAMAZAKI Y, et al. FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis. J Bone Miner Res. 2004;19(3):429-435.
[30] RAMLI FF, CHIN K. A Review of the Potential Application of Osteocyte-Related Biomarkers, Fibroblast Growth Factor-23, Sclerostin, and Dickkopf-1 in Predicting Osteoporosis and Fractures. Diagnostics. 2020;10(3):145.
[31] HEERSPINK HJ, PERKINS BA, FITCHETT DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752-772.
[32] YANG J, ZHANG T, FENG D, et al. A new diagnostic index for sarcopenia and its association with short-term postoperative complications in patients undergoing surgery for colorectal cancer. Colorectal Dis. 2019; 21(5):538-547.